The FDA announced on April 15, 2026 that it is removing 12 peptides from Category 2 of its interim 503A bulk drug substances list. The change is effective April 22, 2026 — seven calendar days after publication. Category 2 is the designation reserved for compounds the agency considers to pose "significant safety concerns." For six years, that label has been the legal reason compounding pharmacies could not prepare BPC-157, TB-500, GHK-Cu, and Melanotan II for patients. After April 22, that label is gone.
The 12 Peptides Coming Off the List
The FDA is removing the following 12 peptide-based bulk drug substances from Category 2. The list breaks into two groups based on when the Pharmacy Compounding Advisory Committee will formally review them for possible inclusion on the 503A bulks list.
Group 1 — PCAC Review July 23-24, 2026
| Peptide | Primary Use | Review Date |
|---|---|---|
| BPC-157 | Gut healing, tissue repair, inflammation | July 23, 2026 |
| KPV | Anti-inflammatory, wound healing | July 23, 2026 |
| MOTs-C | Mitochondrial metabolism, body composition | July 23, 2026 |
| TB-500 | Wound healing, injury recovery | July 23, 2026 |
| Emideltide (DSIP) | Sleep, stress response | July 24, 2026 |
| Epitalon | Telomerase activation, longevity | July 24, 2026 |
| Semax | Cognitive enhancement, neuroprotection | July 24, 2026 |
Group 2 — PCAC Review by February 2027
| Peptide | Primary Use | Review Date |
|---|---|---|
| Cathelicidin LL-37 | Antimicrobial, immune modulation | Early 2027 |
| Dihexa acetate | Cognition, nerve growth | Early 2027 |
| GHK-Cu | Skin, hair, tissue regeneration | Early 2027 |
| PEG-MGF | Muscle repair, hypertrophy | Early 2027 |
| Melanotan II | Pigmentation, libido | Early 2027 |
All 12 removals follow the same mechanism: the original nominators voluntarily withdrew their petitions to keep these substances on Category 2. Once withdrawn, the FDA no longer has an active safety-concern nomination to evaluate, so the substances come off the list by default.
Why This Is a Bigger Deal Than the February Announcement
In February 2026, HHS Secretary Kennedy announced that 14 of the 19 peptides restricted in late 2023 would move from Category 2 back to Category 1. That was a policy signal. Today's action is the mechanism.
Two groups of readers should care about this specifically.
First, buyers who watched the February announcement and assumed GHK-Cu and Melanotan II were lost causes. Our own earlier reclassification coverage noted that GHK-Cu, Melanotan II, PEG-MGF, LL-37, and dihexa were widely expected to remain in Category 2 because of stronger safety concerns cited at the 2024 advisory committee. The April 15 action sweeps all five into the same withdrawal pathway as BPC-157 and TB-500 — they are all off Category 2 as of April 22, and all get a formal PCAC hearing by early 2027.
Second, compounding pharmacies and prescribers. The Category 2 designation was the explicit legal citation pharmacies used to refuse peptide prescriptions. With that designation removed, the peptides enter a regulatory gray zone — not yet approved for the 503A bulks list, but no longer flagged as presenting significant safety risks. Most pharmacies will still wait for a formal PCAC recommendation before compounding, but the legal rationale for blanket refusal is weaker starting April 22.
What This Changes for Buyers — Practical
Compounding pharmacy access is still not open. Removal from Category 2 is not the same as addition to the 503A bulks list. Until the PCAC reviews each peptide and the FDA acts on the recommendation, pharmacies have no authorization to compound these substances for patients. Anyone marketing "FDA-approved compounded BPC-157" between now and then is getting ahead of the regulation.
Research-grade sourcing is still the current access point. The same established peptide vendors that have supplied BPC-157, TB-500, GHK-Cu, and Melanotan II throughout the Category 2 period remain the practical option between now and the PCAC decisions. Prices have not meaningfully moved on today's news because nothing about wholesale peptide supply has changed yet.
The July 23-24 meeting is now the high-leverage date. If the committee votes favorably on the first seven peptides — BPC-157, KPV, MOTs-C, TB-500, DSIP, epitalon, and semax — compounded access through licensed pharmacies could follow as early as late 2026 or early 2027. Submit a public comment before the July 9 deadline if you want your input on the docket: see our public comment deadline guide for the step-by-step.
Current Vendor Options for the 12 Peptides
Top BPC-157 Vendors
Ranked by price, COA availability, and reputation
Top TB-500 Vendors
Ranked by price, COA availability, and reputation
Top GHK-Cu Vendors
Ranked by price, COA availability, and reputation
Top Melanotan II Vendors
Ranked by price, COA availability, and reputation
For the full vendor comparison across all 12 peptides:
- Best BPC-157 vendors — the highest-search peptide on the list
- Best TB-500 vendors — often paired with BPC-157
- Best GHK-Cu vendors — skin, hair, and copper-peptide regeneration
- Best Melanotan II vendors — pigmentation and libido
- Best KPV vendors — focused anti-inflammatory
- Best MOTs-C vendors — mitochondrial peptide
- Best Epitalon vendors — telomerase-activating longevity peptide
- Best Semax vendors — cognitive peptide
- All peptide coupon codes — current discounts up to 50%
